Julie Kim
Takeda
President, U.S. Business Unit and U.S. Country Head
Julie Kim is President of Takeda’s U.S. Business Unit and U.S. Country Head.
Ms. Kim has nearly 30 years of experience in health care, 15 of those in international leadership positions. She joined Takeda in 2019 through the acquisition of Shire, where throughout her time she held many diverse roles with increasing responsibility through her time at Baxter/Baxalta/Shire. These included roles as Global Franchise Head in different therapy areas, international market access, country and regional general management, marketing, and emerging market development.
In 2020, Ms. Kim was instrumental in bringing together the majority of the plasma companies to form the CoVIg-19 Plasma Alliance, in an effort to develop and manufacture a potential therapy to treat COVID-19.
Ms. Kim is a member of the Board of Directors of Croda International Plc., a company that uses smart science to create high performance ingredients and technologies that improve lives. Known as a strong, collaborative leader, she has been named on the 2022 PharmaVoice 100 list as well as the Fierce Pharma's 2020 list of Fiercest Women in Life Sciences.
Prior to joining the biopharmaceutical industry, Ms. Kim worked in health care consulting in the U.S.
Ms. Kim holds an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a BA in Economics from Dartmouth College.
Ms. Kim has nearly 30 years of experience in health care, 15 of those in international leadership positions. She joined Takeda in 2019 through the acquisition of Shire, where throughout her time she held many diverse roles with increasing responsibility through her time at Baxter/Baxalta/Shire. These included roles as Global Franchise Head in different therapy areas, international market access, country and regional general management, marketing, and emerging market development.
In 2020, Ms. Kim was instrumental in bringing together the majority of the plasma companies to form the CoVIg-19 Plasma Alliance, in an effort to develop and manufacture a potential therapy to treat COVID-19.
Ms. Kim is a member of the Board of Directors of Croda International Plc., a company that uses smart science to create high performance ingredients and technologies that improve lives. Known as a strong, collaborative leader, she has been named on the 2022 PharmaVoice 100 list as well as the Fierce Pharma's 2020 list of Fiercest Women in Life Sciences.
Prior to joining the biopharmaceutical industry, Ms. Kim worked in health care consulting in the U.S.
Ms. Kim holds an MBA from the J. L. Kellogg Graduate School of Management at Northwestern University and a BA in Economics from Dartmouth College.